TargetMol

MDK5466

Product Code:
 
TAR-T24438
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T24438-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24438-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24438-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.
CAS:
852045-46-6
Formula:
C21H23N3OS
Molecular Weight:
365.5
Purity:
0.98
SMILES:
C(CN1CCCC1)Oc1ccc(Nc2ncc(s2)-c2ccccc2)cc1

References

1. Cortes J, Perl AE, D?hner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Kr?mer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 May 30. pii: S1470-2045(18)30240-7. doi: 10.1016/S1470-2045(18)30240-7. [Epub ahead of print] PubMed PMID: 29859851. 2. Al-Fayoumi S, Hashiguchi T, Shirakata Y, Mascarenhas J, Singer JW. Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. J Exp Pharmacol. 2018 May 9;10:9-17. doi: 10.2147/JEP.S150729. eCollection 2018. PubMed PMID: 29785143; PubMed Central PMCID: PMC5953271. 3. Osanto S, van der Hulle T. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Ther Adv Urol. 2018 Jan 9;10(3):109-123. doi: 10.1177/1756287217748867. eCollection 2018 Mar. Review. PubMed PMID: 29662541; PubMed Central PMCID: PMC5896860. 4. Gorcea CM, Burthem J, Tholouli E. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Future Oncol. 2018 Mar 2. doi: 10.2217/fon-2017-0582. [Epub ahead of print] PubMed PMID: 29498296.